Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Comparison of Haloperidol 5mg IM vs Droperidol 2.5mg and Ondansetron for the Treatment of Hyperemesis in Cannabis Hyperemesis Syndrome

NCT05065567 is registered in ClinicalTrials.gov with Corewell Health South as lead sponsor.

NCT NCT05065567
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05065567 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Comparison of Haloperidol 5mg IM vs Droperidol 2.5mg and Ondansetron for the Treatment of Hyperemesis in Cannabis Hyperemesis Syndrome
Lead sponsor
Corewell Health South
Phase
Phase 3
Overall status
Terminated
Start date
August 30, 2021
Completion date
November 20, 2023
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cyclic vomiting syndrome